141 related articles for article (PubMed ID: 36244672)
1. CHI3L1 predicted in malignant entities is associated with glioblastoma immune microenvironment.
Li F; Qi B; Yang L; Wang B; Gao L; Zhao M; Luo L
Clin Immunol; 2022 Dec; 245():109158. PubMed ID: 36244672
[TBL] [Abstract][Full Text] [Related]
2. High CHI3L1 expression is associated with glioma patient survival.
Steponaitis G; Skiriutė D; Kazlauskas A; Golubickaitė I; Stakaitis R; Tamašauskas A; Vaitkienė P
Diagn Pathol; 2016 Apr; 11():42. PubMed ID: 27121858
[TBL] [Abstract][Full Text] [Related]
3. Chitinase-3 like-protein-1 promotes glioma progression via the NF-κB signaling pathway and tumor microenvironment reprogramming.
Zhao T; Zeng J; Xu Y; Su Z; Chong Y; Ling T; Xu H; Shi H; Zhu M; Mo Q; Huang X; Li Y; Zhang X; Ni H; You Q
Theranostics; 2022; 12(16):6989-7008. PubMed ID: 36276655
[No Abstract] [Full Text] [Related]
4. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
5. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
6. Histone acetylation gene-based biomarkers as novel markers of the immune microenvironment in glioblastoma.
Yan X; Feng L; Xu Z; Chen W; Yan H; Wu P; Ding C; Zhu X; Lu Y
J Gene Med; 2023 Oct; 25(10):e3511. PubMed ID: 37097165
[TBL] [Abstract][Full Text] [Related]
7. Epithelial Membrane Protein-3 and Chitinase-3-like Protein-1 as New Prognostic Predictors of Glioma, a Two-Gene Study.
Shen K; Zhu J; Zhou S; Jin X; Zhai W; Sun L; Wu J; Yu Z
Curr Oncol; 2023 Sep; 30(10):8686-8702. PubMed ID: 37887529
[TBL] [Abstract][Full Text] [Related]
8. Impact of beta-2 microglobulin expression on the survival of glioma patients via modulating the tumor immune microenvironment.
Tang F; Zhao YH; Zhang Q; Wei W; Tian SF; Li C; Yao J; Wang ZF; Li ZQ
CNS Neurosci Ther; 2021 Aug; 27(8):951-962. PubMed ID: 33960680
[TBL] [Abstract][Full Text] [Related]
9. TIMP1/CHI3L1 facilitates glioma progression and immunosuppression via NF-κB activation.
Xu J; Wei C; Wang C; Li F; Wang Z; Xiong J; Zhou Y; Li S; Liu X; Yang G; Han L; Zhang J; Zhang S
Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167041. PubMed ID: 38290591
[TBL] [Abstract][Full Text] [Related]
10. Differential regulation of the pro-inflammatory biomarker, YKL-40/CHI3L1, by PTEN/Phosphoinositide 3-kinase and JAK2/STAT3 pathways in glioblastoma.
Wang Y; Wong CW; Yan M; Li L; Liu T; Or PM; Tsui SK; Waye MM; Chan AM
Cancer Lett; 2018 Aug; 429():54-65. PubMed ID: 29729901
[TBL] [Abstract][Full Text] [Related]
11. Chi3l1 Is a Modulator of Glioma Stem Cell States and a Therapeutic Target in Glioblastoma.
Guetta-Terrier C; Karambizi D; Akosman B; Zepecki JP; Chen JS; Kamle S; Fajardo JE; Fiser A; Singh R; Toms SA; Lee CG; Elias JA; Tapinos N
Cancer Res; 2023 Jun; 83(12):1984-1999. PubMed ID: 37101376
[TBL] [Abstract][Full Text] [Related]
12. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
Pachocki CJ; Hol EM
J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
[TBL] [Abstract][Full Text] [Related]
13. CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas.
Guan X; Zhang C; Zhao J; Sun G; Song Q; Jia W
EBioMedicine; 2018 Sep; 35():233-243. PubMed ID: 30131308
[TBL] [Abstract][Full Text] [Related]
14. In silico analysis identified miRNA‑based therapeutic agents against glioblastoma multiforme.
Xiong DD; Xu WQ; He RQ; Dang YW; Chen G; Luo DZ
Oncol Rep; 2019 Apr; 41(4):2194-2208. PubMed ID: 30816530
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms underlying gliomas and glioblastoma pathogenesis revealed by bioinformatics analysis of microarray data.
Vastrad B; Vastrad C; Godavarthi A; Chandrashekar R
Med Oncol; 2017 Sep; 34(11):182. PubMed ID: 28952134
[TBL] [Abstract][Full Text] [Related]
16. CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells.
Ku BM; Lee YK; Ryu J; Jeong JY; Choi J; Eun KM; Shin HY; Kim DG; Hwang EM; Yoo JC; Park JY; Roh GS; Kim HJ; Cho GJ; Choi WS; Paek SH; Kang SS
Int J Cancer; 2011 Mar; 128(6):1316-26. PubMed ID: 20506295
[TBL] [Abstract][Full Text] [Related]
17. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value and immune cell infiltration of hypoxic phenotype-related gene signatures in glioblastoma microenvironment.
Xiao K; Tan J; Yuan J; Peng G; Long W; Su J; Xiao Y; Xiao Q; Wu C; Qin C; Hu L; Liu K; Liu S; Zhou H; Ning Y; Ding X; Liu Q
J Cell Mol Med; 2020 Nov; 24(22):13235-13247. PubMed ID: 33009892
[TBL] [Abstract][Full Text] [Related]
19. Targeting protumor factor chitinase-3-like-1 secreted by Rab37 vesicles for cancer immunotherapy.
Yang PS; Yu MH; Hou YC; Chang CP; Lin SC; Kuo IY; Su PC; Cheng HC; Su WC; Shan YS; Wang YC
Theranostics; 2022; 12(1):340-361. PubMed ID: 34987649
[No Abstract] [Full Text] [Related]
20. Multi-omics analyses of CD276 in pan-cancer reveals its clinical prognostic value in glioblastoma and other major cancer types.
Dai L; Guo X; Xing Z; Tao Y; Liang W; Shi Z; Hu W; Zhou S; Wang X
BMC Cancer; 2023 Jan; 23(1):102. PubMed ID: 36717836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
